Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
06/2003
06/24/2003US6582700 Linear antigen supporting units
06/24/2003US6582699 Combination of outer-polysaccharides extracted from Brucella comprises "A" outer-polysaccharide and "M" outer-polysaccharide and "R" protein antigens.
06/24/2003US6582697 Administering a synthetic conjugate comprising a carbohydrate antigenic determinant and an immunogenic carrier not naturally conjugated with said determinant; tumor prophylaxis and therapy for example
06/24/2003US6582618 Method of determining etch endpoint using principal components analysis of optical emission spectra
06/24/2003US6582391 Extracorporeal device comprising insoluble collagen fibrils; embedded within matrix are cultured vertebrate cells which secrete polypeptides; shunting patient's blood through apparatus and back into patient; polypeptide mixes with blood
06/24/2003US6581607 Method and system for use in treating a patient with a biological substance to optimize therapy and prevent an adverse response
06/24/2003CA2223694C Isolated nucleic acid molecules, peptides which form complexes with mhc molecule hla-a2 and uses thereof
06/24/2003CA2171544C Peptides that elicit neutralizing antibodies against genetically divergent hiv-1 strains
06/24/2003CA2165566C Conotoxins having acetylcholin receptor binding properties
06/21/2003CA2365811A1 A new gene therapy using antisense strategy to estrogen receptors (er .alpha. and/or er .beta.) to optimize vascular healing and cardioprotection after vascular injury
06/19/2003WO2003050504A2 Methods and compositions to treat cardiovascular disease usin g 1419, 58765 and 2201
06/19/2003WO2003050502A2 Prospective identification and characterization of breast cancer stem cells
06/19/2003WO2003050283A2 A structure for presenting desired peptide sequences
06/19/2003WO2003050271A2 In vitro production of dendritic cells from cd14+ monocytes
06/19/2003WO2003050268A2 Enhancement of the immune response using cd36-binding domain
06/19/2003WO2003050260A2 Streptavidin expressed gene fusions and methods of use thereof
06/19/2003WO2003050258A2 Endogenous retrovirus polypeptides linked to oncogenic transformation
06/19/2003WO2003050255A2 Nucleic acid and corresponding protein entitled 193p1e1b useful in treatment and detection of cancer
06/19/2003WO2003050241A2 Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation
06/19/2003WO2003050140A1 Tumor antigens
06/19/2003WO2003050135A2 Use a parapox b2l protein to modify immune responses to administered antigens
06/19/2003WO2003050122A2 Mitotic kinesin inhibitors
06/19/2003WO2003050108A1 Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
06/19/2003WO2003050064A2 Mitotic kinesin inhibitors
06/19/2003WO2003049773A1 Methods for inhibiting ocular processes
06/19/2003WO2003049767A2 Method of large scale production of hepatitis a virus
06/19/2003WO2003049766A2 Method of purifying hepatitis a virus particles and vaccine preparation
06/19/2003WO2003049765A2 Enveloped virus vaccine and method for production
06/19/2003WO2003049764A1 Composition for viral preservation
06/19/2003WO2003049763A1 Composition for the preservation of viruses
06/19/2003WO2003049762A2 Immunisation against chlamydia trachomatis
06/19/2003WO2003049755A1 Enhancement of immune responses by 4-1bb-binding agents
06/19/2003WO2003049752A2 Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation
06/19/2003WO2003049703A2 Chimeric infectious dna clones, chimeric porcine circoviruses and uses thereof
06/19/2003WO2003049694A2 Methods of therapy for non-hodgkin's lymphoma
06/19/2003WO2003049683A2 Use of parapox b2l protein to treat cancer and modify immune responses
06/19/2003WO2003049678A2 Mitotic kinesin inhibitors
06/19/2003WO2003049673A2 Methods and compositions for control of bone formation via modulation of sympathetic tone
06/19/2003WO2003049670A2 Adjuvant formulations for bacterial and virus vaccines and method of making same
06/19/2003WO2003049667A2 The method of treating cancer
06/19/2003WO2003035681A3 Mycobacterial genes down-regulated during latency
06/19/2003WO2003009777A3 Delivery of therapeutic capable agents
06/19/2003WO2002077237A3 Transporters and ion channels
06/19/2003WO2002077020A3 Virulence genes in h. influenzae
06/19/2003WO2002062847A3 Superficial zone protein and methods of making and using same
06/19/2003WO2002044342A9 Hematopoietic cell e-selection/l-selectin ligand polypeptides and methods of use thereof
06/19/2003WO2002043660A3 Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
06/19/2003WO2002030979A3 Polypeptides homologous to thymosin, ephrin a receptors, and fibromodulin, and polynucleotides encoding same
06/19/2003WO2002029058A3 Human proteins, polynucleotides encoding them and methods of using the same
06/19/2003WO2002004664A3 Genes comprising coding mononucleotide microsatellites or dinucleotide microsatellites that can be isolated from tumour cells
06/19/2003WO2002004514A3 Compositions and methods for the therapy and diagnosis of lung cancer
06/19/2003US20030114659 Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
06/19/2003US20030114658 Vascular endothelial growth factor D (VEGF-D) antibodies and vectors, and methods of use
06/19/2003US20030114654 Antithrombin nucleotides and proteins from horn fly
06/19/2003US20030114652 Hybrid polypeptide; genetic engineering
06/19/2003US20030114434 Extended duration light activated cancer therapy
06/19/2003US20030114410 Angiogenesis inhibition by administering into the tissue a molecule ,e.g., novel platelet factor 4 binding protein, to deactivate a lysyl oxidase; antimetastasis, -carcinogenic and -tumor agents; suppression of fibrosis
06/19/2003US20030114398 Monoclonal antiidiotype antibody 1A7 eliciting an anti-ganglioside GD2 response and overcomes immune tolerance; detecting an anti-GD2 antibody bound to a tumor cell; kits; melanoma, neuroblastoma, glioma, soft tissue sarcoma
06/19/2003US20030114368 Immunotoxins directed against malignant cells
06/19/2003US20030114358 Proteases, lipases and phosphorylases inhibitors
06/19/2003US20030113900 Incubation, culture product, drying, stabilization; storage stability; freeze drying in presence of trehalose
06/19/2003US20030113867 Muscle receptor proteins; transport proteins; antitumor agents; antiinflammatory agents; antidiabetic agents; modulation of muscle contraction
06/19/2003US20030113845 Lyases; bactericides; gene knockout; animal husbandry
06/19/2003US20030113840 25 human secreted proteins
06/19/2003US20030113820 Monoclonal anti-idiotypic antibody; antitumor agents; anticarcinogenic agents; antiproliferative agents; immunotherapy; hormone antagonist therapy
06/19/2003US20030113818 Monoclonal anti-idiotypic antibody; antitumor agents; anticarcinogenic agents; antiproliferative agents; immunotherapy; hormone antagonist therapy
06/19/2003US20030113795 Membrane protein; cytokines; antitumor agents; anticarcinogenic agents; antiinflammatory agents; cancer diagnosis
06/19/2003US20030113793 Secreted and transmembrane polypeptides and nucleic acids encoding the same
06/19/2003US20030113789 Protease peptides; anticarcinogenic agents; neurotransmitters; antidiabetic agents
06/19/2003US20030113788 Inducing immune response in animals; vaccines; anticarcinogenic agents; viricides; bactericides; parasitides
06/19/2003US20030113772 DNA encoding human alpha 1 adrenergic receptors and uses thereof
06/19/2003US20030113771 DNA encoding human alpha 1 adrenergic receptors and uses thereof
06/19/2003US20030113764 Compositions and methods for the treatment of tumors
06/19/2003US20030113350 Immunocarrier and a conjugate of a polysaccharide or glycopeptide surface antigen from a bacterial strain
06/19/2003US20030113347 Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
06/19/2003US20030113346 Genome which overexpresses G protein to increase apoptosis in infected cells
06/19/2003US20030113345 Hybrid heat labile enterotoxin holotoxin comprising the a-subunit of the heat labile toxin of escherichia coli (lt-a) and the b-subunit of the cholera enterotoxin of vibrio cholerae (ct-b); vaccines
06/19/2003US20030113344 Induce an immunogenic response in animals to non-typable Haemophilus influenzae
06/19/2003US20030113343 Identification and characterization of novel pneumococcal choline binding protein, CbpG, and diagnostic and therapeutic uses thereof
06/19/2003US20030113342 Recombinant hepatitis b surface antigen
06/19/2003US20030113341 Methods of using FLT3-ligand in the treatment of cancer
06/19/2003US20030113339 Methods to improve immunogenicity of antigens and specificity of antibodies
06/19/2003US20030113338 Immunogenic detoxified mutant e. coli lt-a toxin
06/19/2003US20030113337 High efficiency tissue specific compound delivery system using streptavidin-protein a fusion protein
06/19/2003US20030113334 Cytotoxic antibodies specifically bind to proteins which were expressed in lymphatic tumors
06/19/2003US20030113333 A kit containing a binding protein and a carrier molecule, binds with a hapten moiety and binds with a target antigen; monoclonal antibodies and engineered antibodies
06/19/2003US20030113331 An antagonist specifically binds to a denatured collagens; antitumor agents, antimetastasis agents; monoclonal antibodies; drug screening for denatured collagen antagonists
06/19/2003US20030113323 High mobility group proteins; diagnostic monitoring the severity or potential lethality of sepsis or septic shock, measuring the serum protein concentration of patient, treating weight loss or obesity
06/19/2003US20030113316 Stable lyophilized pharmaceutical formulation of IgG antibodies
06/19/2003US20030113311 Pertussis toxin and analogs exhibit an adenosine-5* diphosphate-ribosyltransferase activity, useful in promoting prophylactic and/or therapeutic responses against another target antigen in a mammal patient
06/19/2003US20030113296 A tissue-specific transcriptional regulatory sequence(promoter or enhancer) operably linked to the coding region of a gene that is essential of replication of the vector (DNA tumor viral vector)
06/19/2003US20030113292 Interferon-gamma-inducing factor (IGIF/IL-18); promoting differentiation of CD4-lymphocytes
06/19/2003US20030113264 Non-Invasive localization of a light-emitting conjugate in a mammal
06/19/2003CA2784260A1 Chimeric infectious dna clones, chimeric porcine circoviruses and uses thereof
06/19/2003CA2493444A1 Adjuvant formulations for bacterial and virus vaccines and method of making same
06/19/2003CA2470104A1 Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation
06/19/2003CA2469889A1 Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
06/19/2003CA2469802A1 A structure for presenting desired peptide sequences
06/19/2003CA2469792A1 In vitro production of dendritic cells from cd14+ monocytes especially for the preparation of suspension, monolayer and three-dimensional cell and/or tissue models, and use of these models
06/19/2003CA2469620A1 Immunisation against chlamydia trachomatis
1 ... 1237 1238 1239 1240 1241 1242 1243 1244 1245 1246 1247 1248 1249 1250 1251 1252 1253 1254 1255 1256 1257 ... 1823